Effect of an angiotensin-II type-1 receptor blocker, candesartan on hepatic fibrosis in chronic hepatitis C: A prospective study

Hepato-Gastroenterology

Volumn 56, Issue 93, 2009, Pages 1100-1104

  Ueki, Masaru ^a   Koda, Masahiko ^a   Shimizu, Tatsunori ^a   Mitsuta, Akeri ^a   Yamamoto, Tetsuo ^a   Murawaki, Yoshikazu ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

AT1 receptor antagonist; Candesartan; Chronic hepatitis C; Fibroindex; Noninvasive index of liver fibrosis

Indexed keywords

CANDESARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; AST TO PLATELET RATIO INDEX; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; FIBROINDEX; FOLLOW UP; FORN INDEX; HEPATITIS C; HUMAN; HYPERTENSION; LIVER FIBROSIS; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; ANALYSIS OF VARIANCE; LIVER CIRRHOSIS; TREATMENT OUTCOME;

AGED; ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; PROSPECTIVE STUDIES; TETRAZOLES; TREATMENT OUTCOME;

EID: 70350511929     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, et al.: Angiotensin-II type 1 interaction is a major regulator for hepatic fibrosis development in rats. Hepatology 2001; 34: 745-750. (Pubitemid 32927999)
2. Kurikawa N, Suga M, Kuroda S, Yamada K, Ishikawa H: An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental hepatic fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br J Pharmacol 2003; 139: 1085-1094. (Pubitemid 36920670)
3. Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD, et al.: Angiotensin-Converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001; 121: 148-155. (Pubitemid 32591525)
4. Tuncer I, Ozbek H, Ugras S, Bayram I: Anti-fibrogenic effects of captopril and candesartan cilexitil on the hepatic fibrosis development in rat. Exp Toxic Pathol 2003; 55: 159-166.
5. Ueki M, Koda M, Yamamoto S, Matsunaga Y, Murawaki Y: Preventive and therapeutic effects of angiotensin-II type-1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats. J Gastroenterol 2006; 41: 996-1004. (Pubitemid 44741413)
6. Terui Y, Saito T, Watanabe H, Togashi H, Kawata S: Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 2002; 36: 1022-1022.
7. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, et al.: Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepetitis. Hepatology 2004; 40: 1222-1225. (Pubitemid 39425579)
8. Rimola A, Londono MC, Guevara G, Bruguera M, Navasa M, Forns X, et al.: Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 2004; 78: 686-691. (Pubitemid 39244729)
9. Sookoian S, Fernandez MA and Castano G: Effects of six months Losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study, World J Gastroenterol 2005; 11: 7560-7563. (Pubitemid 43168416)
10. Schneider AW, Falk JF, Klein CP: Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999; 29: 334-339. (Pubitemid 29088434)
11. Gonzalez-Abraldes J, Albillos A, Banares R, Arbol LRD, Moitinho E, Rodriqueez C, Gonzalez M, et al.: Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001; 121: 382-388.
12. Schepke M, Werner EVA, Biecker E, Schiedermaier P, Heller J, Neef M, Stoffel-Wagner B, et al.: Hemodynamic effects of the angiotensin II receptor antagonist irbestatin in patients with cirrhosis and portal hypertension. Gastroenterology 2001; 121: 389-395. (Pubitemid 32729386)
13. Forns X, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, et al.: Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-992.
14. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al.: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526. (Pubitemid 36919874)
15. Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y: Fibroindex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007; 45: 297-306. (Pubitemid 46374586)
16. The French METAVIR Cooperative Study Group: Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
17. Rousselet MC, Michalak S, Dupré F, Croué A, Bedossa P, Saint-André JP, et al.: Hepatitis Network 49. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41: 257-264. (Pubitemid 40165369)
18. Kanno K, Tazuma S, Nishioka T, Hyogo H, Chayama K: Angiotensin II participates in hepatic inflammation and fibrosis through MCP-1 expression. Dig Dis Sci 2005; 50: 942-948. (Pubitemid 40684916)
19. Takano M, Itoh N, Yayama K, Yamano M, Ohtani R, Okamoto H: Interleukin-6 as a mediator responsible for inflammation-induced increase in plasma angiotensinogen. Biochem Pharmacol 1993; 45: 201-206. (Pubitemid 23023757)
20. Debernardi-Venon W. Barletti C, Alessandria C, Marzano A, BaronioM, Todros L, Saracco G, Repici A, Rizzetto M: Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension. Dig Dis Sci 2002; 47: 401-404. (Pubitemid 34124002)
21. Hidaka H, Kokubu S, Nakazawa T, Okuwaki Y, Ono K, Watanabe M, Shibuya A, Saigenji K: New angiotensin II type 1 receptor blocker olmesartan improves portal hypertension in patients with cirrhosis. Hepatol Res 2007; 37: 1011-1017. (Pubitemid 350028327)
22. Debernardi-Venon W. Martini S, Biasi F, Vizio B, Termine A, Poli G, Brunello F, Alessandria C, Bonardi R, Saracco G, Rizzetto M, Marzano A: AT1 receptor antagonist candesartan in selected cirrhotic patients: Effect on portal pressure and liver fibrosis markers. J Hepatol 2007; 46: 1026-1033. (Pubitemid 46669730)